<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Scedosporium and Lomentospora infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Scedosporium and Lomentospora infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Scedosporium and Lomentospora infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia F Costa, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara D Alexander, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>During the past few decades, opportunistic fungal pathogens have become increasingly recognized as a cause of infection in severely ill or immunocompromised patients [<a href="#rid1">1,2</a>]. Although <em>Aspergillus </em>species remain the most common mold to cause invasive infection, other pathogens are becoming more common [<a href="#rid1">1-3</a>]. Among these, members of the <em>Scedosporium apiospermum</em> complex and <em>Lomentospora prolificans</em> are considered major human pathogens [<a href="#rid4">4</a>].</p><p>This topic will discuss the diagnosis and treatment of <em>Scedosporium</em> and <em>Lomentospora</em> infections. The epidemiology, mycology, and clinical manifestations of <em>Scedosporium </em>and <em>Lomentospora</em> infections are discussed elsewhere (see  <a class="medical medical_review" href="/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>). Other emerging fungal infections are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3033.html" rel="external">"Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection"</a> and  <a class="medical medical_review" href="/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">SUSCEPTIBILITY TESTING</span><span class="headingEndMark"> — </span>Given the varying in vitro activity of antifungal agents against members of the <em>S. apiospermum</em> complex and <em>L. prolificans</em>, we typically ask for susceptibility testing of isolates from patients with infections caused by these pathogens. Results of susceptibility testing should be interpreted along with multiple factors that impact drug activity in vivo. Factors that also play a role in determining the outcome of fungal infection include: immune status of the patient (immunocompetent versus immunosuppressed) and possible modulation of immunosuppression, timing of diagnosis (early versus late), extent of disease (localized versus disseminated), amenability to surgical intervention (eg, drainage, debridement, debulking), bioavailability and efficacy of antifungal drug at site of infection (pharmacokinetic and pharmacodynamic parameters), and host metabolic parameters, among others [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H624145376"><span class="h2">Definitions</span><span class="headingEndMark"> — </span>The term "MIC" refers to the minimum inhibitory concentration of an antifungal agent required to inhibit growth of an organism. MIC<sub>50</sub> refers to 50 percent inhibition; MIC<sub>90</sub> refers to 90 percent inhibition.</p><p>The term "MEC," minimal effective concentration, refers to the lowest concentration of an antifungal agent that leads to aberrant growth, which is the growth of small, rounded, compact hyphal forms as compared with the hyphal growth seen in the growth control well [<a href="#rid6">6</a>]. MECs are generally used for the echinocandins. MEC<sub>50</sub> is the concentration at which 50 percent of isolates showed aberrant growth, and MEC<sub>90</sub> is the concentration at which 90 percent of isolates showed aberrant growth.</p><p>The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) has an approved standard method for antifungal susceptibility testing of filamentous fungi [<a href="#rid6">6</a>]. The M38 method is applicable to <em>Aspergillus</em>, <em>Fusarium</em>, <em>Scedosporium</em>, <em>Lomentospora</em>, and the Mucorales for testing amphotericin B, the azole, and echinocandin antifungal agents. Reference ranges for amphotericin B, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> (MICs) and <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> (MECs) have been proposed for two quality-control strains of <em>S. apiospermum </em>(ATCC MYA-3635 and ATCC MYA-3634) [<a href="#rid7">7</a>]. However, interpretive clinical breakpoints for antifungal MICs/MECs and <em>Scedosporium</em> spp are not available.</p><p>Antifungal susceptibility testing is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">In vitro data</span><span class="headingEndMark"> — </span>A summary of in vitro activities of selected antifungal agents against <em>Scedosporium</em> is provided in the table  (<a class="graphic graphic_table graphicRef65426" href="/d/graphic/65426.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H11"><span class="h3">Scedosporium apiospermum complex</span><span class="headingEndMark"> — </span>The azoles and amphotericin B have varying levels of activity against the members of the <em>S. apiospermum </em>complex, with the extended-spectrum azoles (eg, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>) typically having the lowest MICs among the antifungal agents  (<a class="graphic graphic_table graphicRef65426" href="/d/graphic/65426.html" rel="external">table 1</a>) [<a href="#rid8">8-12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> is more active against <em>S. apiospermum </em>than <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, or amphotericin B according to several studies [<a href="#rid9">9-11,13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">Isavuconazole</a>, a broad-spectrum triazole approved by the US Food and Drug Administration in 2015 for the treatment of invasive aspergillosis and invasive mucormycosis, has shown in vitro activity against some isolates of <em>S. apiospermum </em>complex<em> </em>[<a href="#rid15">15-17</a>]. In vitro testing of clinical isolates of <em>Scedosporium</em> spp using CLSI broth microdilution suggests that isavuconazole is less potent than <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> based on MIC values [<a href="#rid18">18,19</a>]. Higher MICs were also reported for isavuconazole against <em>Scedosporium</em> spp isolates from Australia, New Zealand, and Spain [<a href="#rid14">14,20,21</a>]. Determining antifungal activity for each unique <em>Scedosporium</em> isolate is necessary since variable resistance may preclude treatment with isavuconazole for different <em>Scedosporium</em> species.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">Terbinafine</a> has generally high MICs against <em>S. apiospermum</em>, although reported MICs are variable and activity is noted for some of the isolates tested [<a href="#rid11">11,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echinocandins have variable MECs depending on the <em>S. apiospermum</em> complex species. <em>S. aurantiacum</em> tends to have higher MEC values for all echinocandins [<a href="#rid13">13,17</a>]. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">Flucytosine</a> and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> have no in vitro activity against <em>S. apiospermum</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Olorofim (formerly F901318) is the first member of the orotomide class of antifungals. It inhibits dihydroorotate dehydrogenase, a key enzyme in the de novo biosynthesis of pyrimidine, possibly affecting fungal cell wall and cell cycle regulation [<a href="#rid23">23</a>]. In vitro testing of clinical isolates from the United States, Australia, Europe, and India reported low MICs for this agent against all <em>Scedosporium</em> spp tested [<a href="#rid20">20,21,24-28</a>]. Laboratory-based studies reveal low in vitro MICs of olorofim, between 0.004 and 0.25 mg/L, against <em>S. apiospermum</em> complex [<a href="#rid28">28</a>]. In vivo, neutropenic mice infected with <em>S. apiospermum</em> and treated with olorofim had improved survival and lower fungal DNA burden compared to control mice [<a href="#rid29">29</a>]. Olorofim is in phase IIb clinical trials against <em>L. prolificans</em>, <em>Scedosporium </em>spp, <em>Aspergillus </em>spp, and other resistant fungi lacking alternative antifungal treatments [<a href="#rid30">30</a>]. The following link (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.f2g.com%2Faccess_olorofim&amp;token=Fi68Z9%2Bl6iNrS%2BOYhGd7T0SVnSshBAcI8QL9sv6vhJCEj15pIrv5Ll%2Ba5NMvOrFE&amp;TOPIC_ID=2429" target="_blank">https://www.f2g.com/access_olorofim</a>) also provides physicians information regarding the clinical trial and expanded access for olorofim. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fosmanogepix, also known as APX001 (formerly E1211), is another first-in-class antifungal agent. This small-molecule antifungal is metabolized to the active moiety manogepix or APX001A (formerly E1210). APX001A targets a highly conserved fungal enzyme, Gwt1, inhibiting a step in fungal cell wall protein synthesis, affecting cell wall integrity [<a href="#rid31">31</a>]. APX001A was tested in vitro against clinical isolates originating from North America, Europe, Asia-Pacific, and Latin America and exhibited low MECs (0.015 to 0.08 mg/L) against <em>Scedosporium</em> spp [<a href="#rid31">31-33</a>]. In vitro testing of manogepix versus comparator antifungal drugs against isolates of <em>S.apiospermum </em>complex<em> </em>showed manogepix to be the most potent agent, with an MEC<sub>50</sub>/MEC<sub>90 </sub>of 0.06/0.12 mg/L [<a href="#rid34">34</a>]. In an immunosuppressed murine model of pulmonary scedosporiosis (<em>S. apiospermum</em>) mice treated with fosmanogepix (plus 1-aminobenzotriazole, a P450 inhibitor) had overall prolonged survival compared with treatment with other antifungals [<a href="#rid33">33</a>]. Conidial tissue burden in lung, kidney, and brain was also lower in the fosmanogepix-treated mice compared with placebo. Brain tissue showed no signs of fungal dissemination in mice treated with fosmanogepix or <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>. Fosmanogepix will be evaluated in comparative phase III clinical trial for invasive fungal infections caused by <em>Aspergillus</em> species or rare molds [<a href="#rid35">35</a>]. </p><p></p><p class="headingAnchor" id="H12"><span class="h3">Lomentospora (formerly Scedosporium) prolificans</span><span class="headingEndMark"> — </span><em>L. prolificans</em> is resistant to most antifungal agents, with high MICs documented for <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a>, <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>. <em>L. prolificans</em> is deemed inherently resistant to amphotericin B and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>  (<a class="graphic graphic_table graphicRef65426" href="/d/graphic/65426.html" rel="external">table 1</a>) [<a href="#rid8">8,9,11-14,16,20,36,37</a>].</p><p><a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">Anidulafungin</a> and <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> demonstrated lower MEC<sub>50</sub> and MEC<sub>90</sub> results compared with <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> for <em>L. prolificans</em> by broth microdilution in one study [<a href="#rid17">17</a>], though in later publications, MECs for the echinocandins are &gt;4 mg/L and usually &gt;8 mg/L against <em>L. prolificans </em>[<a href="#rid13">13,36</a>]. <a class="drug drug_general" data-topicid="131762" href="/d/drug information/131762.html" rel="external">Ibrexafungerp</a>, formerly SCY-078 (MK3118), a glucan-synthase inhibitor that interferes with the cell wall polymer beta-(1,3)-D-glucan, has displayed modest in vitro activity against <em>L. prolificans</em>, with an MEC<sub>90</sub> of 4 mcg/mL [<a href="#rid38">38</a>]. A second-generation fungerp antifungal, SCY-247, has also shown in vitro activity against <em>Scedosporium</em> isolates with slightly lower MICs compared with the parent compound, ibrexafungerp, warranting further study [<a href="#rid39">39</a>].</p><p>The orotomide antifungal agent, olorofim, currently in phase IIb clinical trials [<a href="#rid30">30</a>], has potent in vitro activity against <em>L</em>. <em>prolificans</em>. In vitro testing of clinical <em>L. prolificans </em>isolates from the United States, Australia, and Europe revealed low MICs for olorofim, particularly against panresistant <em>L. prolificans</em> isolates [<a href="#rid20">20,21,24,25,27,28</a>]. Neutropenic mice infected with <em>L. prolificans</em> and treated with olorofim showed improved survival, decreased fungal DNA load, and decreased fungal hyphae in kidney compared to controls [<a href="#rid29">29</a>]. </p><p>Fosmanogepix, the inositol acyltransferase Gwt1 inhibitor also known as APX001, is metabolized to its active moiety manogepix or APX001A. The latter has been tested against clinical isolates of <em>L. prolificans </em>from North America, Europe, Asia-Pacific, and Latin America and exhibited low MECs. MECs ranged from 0.03 to 0.06 mg/L [<a href="#rid31">31-33</a>]. Fosmanogepix will be evaluated in a comparative phase III multicenter clinical trial for invasive fungal infections caused by <em>Aspergillus</em> spp or rare molds [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H13"><span class="h3">Synergistic studies</span><span class="headingEndMark"> — </span>There is no standardized CLSI-approved guideline for performing synergy testing in vitro. Furthermore, no clinical correlation has been demonstrated between in vitro synergy and synergistic activity in vivo. Nevertheless, several antifungal combinations have been tested in vitro to evaluate for synergy, especially for <em>L. prolificans</em> given its high resistance profile.</p><p class="bulletIndent1"><span class="glyph">●</span>Synergy against <em>L. prolificans</em> has been demonstrated with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> plus <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, voriconazole plus <a class="drug drug_general" data-topicid="91793" href="/d/drug information/91793.html" rel="external">miltefosine</a>, and <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> plus terbinafine with in vitro testing of a small number of isolates [<a href="#rid36">36,40-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> appeared synergistic in vitro in one study, but the number of isolates tested was small, and some isolates demonstrated indifference to the combination [<a href="#rid43">43</a>].Further, more recent in vitro testing of voriconazole-micafungin against clinical isolates revealed no synergistic effect [<a href="#rid36">36</a>]. </p><p></p><p class="headingAnchor" id="H17"><span class="h1">ANTIFUNGAL THERAPY</span><span class="headingEndMark"> — </span><em>Scedosporium</em> and <em>Lomentospora</em> infections are associated with a high incidence of disseminated disease and high mortality rates in hematopoietic cell and solid organ transplant recipients; mortality rates have ranged from 40 to 100 percent [<a href="#rid44">44-48</a>]. The outcome of these infections depends on the infecting strain, location of infection, choice of antifungal therapy, feasibility of surgical debridement, and, most importantly, the underlying immune status of the patient.</p><p>The optimal choice and duration of therapy is unknown. Retrospective studies provide support for the use of <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> for the treatment of <em>Scedosporium</em> and <em>Lomentospora</em> infections [<a href="#rid47">47-51</a>], whereas the data regarding the use of other antifungals come from case reports and small observational studies.</p><p class="headingAnchor" id="H416550907"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>The choice of empiric antifungal regimen depends in part upon which species of <em>Scedosporium</em> is causing the infection. Given the rarity of <em>Scedosporium</em> and <em>Lomentospora</em> infections and the relative antifungal resistance of these pathogens, particularly <em>L. prolificans</em>, clinicians should consult with an infectious diseases specialist with experience managing these infections.</p><p class="headingAnchor" id="H18"><span class="h3">Scedosporium apiospermum</span><span class="headingEndMark"> — </span>The antifungal agent with the greatest efficacy against <em>S. apiospermum</em> is <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> [<a href="#rid47">47,49-52</a>]. Many experts empirically treat patients with <em>S. apiospermum</em> infections with voriconazole monotherapy. Global guidelines endorsed by the European Confederation of Medical Mycology (ECMM), the International Society for Human and Animal Mycology (ISHAM), and the American Society for Microbiology (ASM) strongly support voriconazole as first line therapy for <em>Scedosporium</em> spp infections [<a href="#rid53">53</a>]. We agree with this approach. We do not use amphotericin B to treat <em>S. apiospermum </em>complex<em> </em>infections. A retrospective analysis of patients with <em>Scedosporium</em> who received <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> for invasive fungal infections showed poor response rates [<a href="#rid54">54</a>]. Furthermore, animal studies also do not support the use of amphotericin B [<a href="#rid55">55</a>].</p><p>Most clinical data on the treatment of <em>Scedosporium </em>infections are related to the use of <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>A large retrospective study reviewed 107 patients treated for <em>Scedosporium</em> infection with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, 70 of whom had <em>S. apiospermum</em> infection [<a href="#rid47">47</a>]. Forty-five of 70 patients (66 percent) with <em>S. apiospermum</em> infection had successful responses. The most common underlying conditions were solid organ transplant (22 percent), hematologic malignancy (21 percent), and surgery or trauma (15 percent). Cancer patients and hematopoietic cell transplant recipients had the worst outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another case series of 13 transplant recipients with scedosporiosis and an additional 67 cases reported in the literature between 1985 and 2003 were analyzed regarding treatment outcomes [<a href="#rid44">44</a>]. A logistic regression model, using amphotericin B as the comparator, demonstrated that <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> was associated with a trend toward better survival; however, mortality remained greater than 50 percent in those with disseminated disease [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a salvage study that included patients who were refractory or intolerant of antifungals, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> demonstrated a response rate of only 30 percent in the subgroup with <em>Scedosporium</em> infections [<a href="#rid56">56</a>]. Several case reports have suggested potential efficacy of systemic voriconazole in the treatment of disseminated <em>S. apiospermum</em> infection [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based upon a review of the literature from 2000 to 2018 and Fungiscope (an international registry of rare invasive fungal infections), including &gt;200 patients with <em>Scedosporium</em> infection, patients who were treated with voriconazole-based regimens had overall longer survival time and lower 42-day mortality compared with those treated with amphotericin B [<a href="#rid48">48</a>]. Surgical interventions, debridement, or drainage were also performed where feasible, though a survival benefit was not noted. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective observational study spanning January 2005 to March 2017 of 90 proven/probable <em>Scedosporium</em>/<em>Lomentospora</em> infections showed that <em>S. boydii</em> (17 percent) and <em>S. apiospermum </em>(53 percent) were the most frequently isolated <em>Scedosporium </em>species [<a href="#rid49">49</a>]. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> monotherapy was the most frequent treatment, and half of patients infected with <em>Scedosporium</em> received adjunctive surgery. Three-month mortality was 19 percent for patients infected with <em>Scedosporium</em> spp, and higher mortality was noted in those infected with <em>S. boydii</em> [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">In a subset of the above study, 15 patients had osteoarticular infection, 12 of which were due <em>to Scedosporium</em> spp [<a href="#rid50">50</a>]. The majority received both medical and surgical intervention. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> was prescribed to most patients, either as first line monotherapy or as part of dual (four patients) or triple (two patients) combination therapy, and median duration of antifungal treatment was seven months. Fourteen patients had multiple surgical procedures, including open surgical debridement and removal of orthopedic hardware when present. Thr<em>ee Scedosporium </em>spp-infected patients who failed antifungal treatment were eventually cured with antifungal therapy intensification and surgical intervention. All patients were cured or stabilized, and none died from the infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective multi-center study including 24 episodes of proven/probable <em>Scedosporium</em>/<em>L. prolificans</em> infections, spanning January 2005 to April 2021, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> monotherapy was administered in 63 percent with a median duration of therapy of 156 days. Adjunctive surgery (primarily debridement) was performed in 75 percent. At one-month follow-up, 38 percent were deemed treatment success, and treatment success was 71 percent at 18-month follow-up. Survival was longer in patients who were less immunosuppressed, received longer duration of antifungal therapy, and had adjunctive surgery [<a href="#rid51">51</a>].</p><p></p><p>Other azoles have been used in individual cases of <em>Scedosporium</em> infections [<a href="#rid59">59-70</a>] as well as in animal studies [<a href="#rid71">71-73</a>].</p><p>In clinical trials, <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, which has been approved for treating invasive aspergillosis and invasive mucormycosis, was shown to be noninferior to <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> for invasive mold disease caused by <em>Aspergillus</em> spp and other filamentous fungi [<a href="#rid74">74,75</a>]. However, only three patients with <em>Scedosporium</em> infection participated, thus precluding conclusions about efficacy for these infections. </p><p class="headingAnchor" id="H22"><span class="h3">Lomentospora prolificans</span><span class="headingEndMark"> — </span>We typically initiate combination antifungal therapy for patients with <em>L. prolificans </em>infection. In general, we suggest <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> plus <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> in accordance with expert guidelines [<a href="#rid53">53</a>] but also consideration of the addition of an echinocandin [<a href="#rid76">76,77</a>]. However, this fungus is generally resistant to most available antifungals, and there are no definitive data to suggest that these regimens should be preferred over others. In all cases, we check in vitro susceptibilities because the relative efficacy of antifungal agents varies among strains. </p><p>Although <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> appears to have some activity against this organism, minimum inhibitory concentrations (MICs) tend to be high, and the response to therapy varies depending on the site and extent of infection and the underlying immune status of the host. Patients with <em>L. prolificans</em> infection who are not severely immunocompromised and have skin and soft tissue or bone infection have better outcomes with voriconazole than patients with severe immunosuppression (eg, cancer, hematopoietic cell transplantation) or those with respiratory, central nervous system, or disseminated disease.</p><p>Given the aggressive and often fatal nature of infections with <em>L. prolificans</em>, management needs to be tailored to the individual patient. Surgical debridement and optimization of the patient's immune status (eg, reducing immunosuppression when feasible) are key elements that play a role in determining outcome. Some experts give combination antifungal therapy with an extended-spectrum azole (eg, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>) plus <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> or an echinocandin or both. We typically give voriconazole plus terbinafine with or without an echinocandin. The antifungal regimen should be appropriately modified according to in vitro susceptibility results when they become available. In cases for which susceptibility testing reveals no good antifungal options, antifungal agents are maintained while management of the infection and underlying condition are re-evaluated. While an optimal outcome is desired, not all of these cases will achieve a successful result.</p><p>Case-by-case analysis of the patient's underlying disease, treatment regimen, type of <em>Lomentospora</em> infection, pharmacokinetic/pharmacodynamic data, and MIC of the pathogen help ascertain whether <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> may have a role as part of combination therapy. Specific dosing recommendations are not available for terbinafine in <em>L. prolificans</em> infections. In case reports, the combination of terbinafine 250 mg once or twice daily and appropriately dosed <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, along with adjunctive therapies such as surgical debridement, has led to successful outcomes in a few patients [<a href="#rid78">78-83</a>]. Pharmacokinetic modeling shows that terbinafine doses of 500 mg twice daily achieve higher systemic exposure [<a href="#rid84">84</a>] and higher cure rates in patients with sporotrichosis [<a href="#rid85">85</a>]. Whether this dose would apply to treatment of <em>Lomentospora</em> infections as part of combination therapy remains to be determined.</p><p>Mortality rates with <em>L. prolificans</em> infection are high due to resistance to available antifungal agents. A retrospective review showed successful responses to therapy with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> in 16 of 36 patients (44 percent) infected with <em>L. prolificans </em>[<a href="#rid47">47</a>]. Survival rates were significantly lower among patients with <em>L. prolificans</em> compared with those with <em>S. apiospermum</em> infection. However, the specifics regarding underlying disease and site of fungal infection for these cases were not reported.</p><p>Based upon a comprehensive review of the literature and Fungiscope (an international registry of invasive fungal infections) which included 56 patients with <em>L. prolificans</em> infection, mortality was very high regardless of treatment type, although mortality was lower in patients who received voriconazole-based regimens when compared with other antifungal agents (52.6 versus 68.8 percent) [<a href="#rid48">48</a>]. The addition of <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> to <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> did not appear to reduce mortality. There were likely multiple contributors to mortality that may have confounded the analysis (eg, degree of immunosuppression, severity of illness, and organs involved in the infection). </p><p>In a separate review from the Fungiscope registry spanning 2008 to 2019, both <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> based regimens were associated with treatment success. In this review, mortality was reduced with voriconazole-based combination therapy or any combination antifungal therapy when compared with monotherapy [<a href="#rid83">83</a>]. As with the review above, there are multiple contributors to mortality that may have confounded the analysis.</p><p>In a retrospective study conducted in France spanning 12 years, infection with <em>L. prolificans</em> was associated with increased virulence, dissemination, and mortality compared with infection with <em>Scedosporium </em>spp. In this study, most patients with <em>L. prolificans</em> received combination antifungal treatment that included <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>. Surgery was performed in 31 percent of patients. Infection with <em>L. prolificans</em> and lack of antifungal treatment after diagnosis were independent predictors of mortality at three months [<a href="#rid49">49</a>]. </p><p>In a retrospective multi-center Australian study spanning 16 years, combination <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>/<a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> was used for 36 (97 percent) of 37 episodes of <em>L. prolificans </em>infection. Median duration of antifungal treatment was 11 days, and the majority (70 percent) died by one month. Infection with <em>L. prolificans</em>, disseminated infection, and hematopoietic stem cell transplant were associated with mortality. The combination of voriconazole/terbinafine was not observed to confer treatment success or improved survival [<a href="#rid51">51</a>]. </p><p>Sclerokeratitis with <em>L. prolificans</em> has a poor response to therapy with both topical and systemic agents [<a href="#rid86">86</a>]. Endophthalmitis with this mold, be it secondary to trauma or in disseminated infection, also has a poor response to both systemic and intravitreal agents [<a href="#rid87">87,88</a>].</p><p>Case series of immunocompetent individuals with <em>L. prolificans</em> septic arthritis [<a href="#rid89">89-91</a>] and osteomyelitis [<a href="#rid76">76,78</a>] treated with prolonged antifungal agents and surgical debridement (plus local irrigation with polyhexamethylene biguanide in one case) reported improvement in several patients. In a study of 15 cases of localized osteoarticular infection due to <em>Scedosporium </em>or<em> L. prolificans </em>treated with surgery and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> monotherapy or combination therapy, cure or stabilization was achieved in all patients [<a href="#rid50">50</a>]. </p><p>In some, but not all, animal studies, combination therapy appeared to be more effective than monotherapy. As an example, in a murine model of disseminated <em>L. prolificans </em>infection, the combination of <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> with either <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or amphotericin B prolonged survival and decreased colony counts in both the kidneys and brain compared with single-agent and triple-agent therapy [<a href="#rid92">92</a>]. However, neutropenic mice with disseminated <em>L. prolificans</em> treated with <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>, <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, or combination therapy with both agents had poor outcomes [<a href="#rid93">93</a>]. High doses of liposomal amphotericin B reduced colony counts, but toxicity was high and survival shortened. Caspofungin did not reduce colony counts, although, at high doses, it appeared to prolong survival. The combination of liposomal amphotericin B and caspofungin was no better than liposomal amphotericin B alone.</p><p class="headingAnchor" id="H683955949"><span class="h3">Scedosporium aurantiacum</span><span class="headingEndMark"> — </span>Most clinical cases of <em>S. aurantiacum</em> infection have been reported from Australia, where it has been associated with chronic lung disease [<a href="#rid94">94</a>]. A few invasive cases have been described, but none involved the brain or skin. Low <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> MICs suggest that these agents may be effective for <em>S. aurantiacum</em> infections. Some studies have shown that the echinocandins all have higher minimum effective concentrations (MECs) to <em>S. aurantiacum</em> compared with other species in the <em>S. apiospermum</em> complex [<a href="#rid17">17,95-98</a>]. The new antifungal agents, olorofim and fosmanogepix, have both exhibited low in vitro MIC values against <em>S. aurantiacum </em>[<a href="#rid20">20,21,24,25,32,99</a>]. </p><p>Further studies are needed to correlate MIC data to clinical outcome.</p><p class="headingAnchor" id="H416550690"><span class="h2">Voriconazole dosing and monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> is available in both intravenous (IV) and oral formulations [<a href="#rid100">100-102</a>]. The recommended dosing regimen is 6 mg/kg IV every 12 hours on day 1 followed by 4 mg/kg IV every 12 hours thereafter. We suggest monitoring serum voriconazole trough concentrations in all patients receiving oral or IV voriconazole for invasive <em>Scedosporium</em> or <em>Lomentospora</em> infection. We suggest checking a trough concentration five to seven days into therapy. A goal of achieving serum trough concentrations &gt;1 mcg/mL and &lt;5.5 mcg/mL has been suggested [<a href="#rid103">103</a>], but we prefer concentrations between 2 and 5.5 mcg/mL.</p><p>When the patient is able to take oral medications, one can consider switching to the oral form. Optimal oral dosing is a matter of controversy. The currently recommended dose of 200 mg orally every 12 hours has been noted to result in low or even unmeasurable serum concentrations in a substantial proportion of patients, and high concentrations may be associated with excessive toxicities [<a href="#rid103">103</a>]. The dose of oral <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> can be increased to 4 mg/kg orally every 12 hours (or 300 mg orally every 12 hours) in patients with disease progression.</p><p>We suggest monitoring serum <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> trough concentrations in all patients receiving oral or IV voriconazole for invasive <em>Scedosporium</em> or <em>Lomentospora</em> infection. We suggest checking a trough concentration five to seven days into therapy. A goal of achieving serum trough concentrations &gt;1 mcg/mL and &lt;5.5 mcg/mL has been suggested [<a href="#rid103">103</a>], but we prefer concentrations between 2 and 5.5 mcg/mL. Trough concentrations below 1 mcg/mL warrant an increase in the voriconazole dose and appropriate subsequent monitoring [<a href="#rid52">52</a>]. On the other hand, serum drug concentrations above 5.5 mcg/mL warrant a reduction in the voriconazole dose because they have been associated with an increased risk of toxicity [<a href="#rid103">103,104</a>]. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p>As with other triazoles, use of this agent requires careful monitoring due to potential interactions with other medications, including calcineurin inhibitors, via inhibition of CYP450 enzymes [<a href="#rid105">105,106</a>]. Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. An overview of drug interactions with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p>The adverse effects associated with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> are also discussed separately. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.)</p><p class="headingAnchor" id="H336450432"><span class="h2">Duration</span><span class="headingEndMark"> — </span>Antifungal therapy is generally continued until all signs and symptoms of the infection have resolved and often longer in patients with persistent immune defects. Radiographic abnormalities should have stabilized and signs of active infection should have disappeared before treatment is discontinued. For most immunocompromised patients, antifungal therapy will continue for months or even years in some cases.</p><p class="headingAnchor" id="H830568"><span class="h1">SURGICAL DEBRIDEMENT</span><span class="headingEndMark"> — </span>Given the poor response to antifungal therapies alone, surgical debridement (in addition to antifungal therapy) is encouraged whenever possible. Surgical debridement can help to decrease the burden of organisms present and has been associated with improved outcomes [<a href="#rid44">44,107</a>]. Adjunctive surgery has been reported for <em>Scedosporium</em> soft tissue infection [<a href="#rid49">49-51,65</a>], osteomyelitis [<a href="#rid50">50,66,67,76,78</a>], pneumonia [<a href="#rid59">59,62</a>], and brain abscesses [<a href="#rid70">70,108-110</a>].</p><p>In a study of 55 pediatric patients with invasive <em>Scedosporium</em> spp and <em>L. prolificans </em>infection, 96 percent were treated with antifungals independent of the causative fungus and 62 percent received surgical intervention [<a href="#rid111">111</a>]. Most patients undergoing surgical intervention were immunocompetent, and procedures included surgical debridement of bone and joint infections, drainage of central nervous system abscess, and surgical management of eye infections. Lower risk of death was noted if <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> and surgery were included as part of the treatment regimen.</p><p>In adults with <em>L. prolificans</em> infection, surgical intervention was associated with higher 28-day survival rates, though the number of patients was small [<a href="#rid83">83</a>]. </p><p>Management of mold endophthalmitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds"</a>.)</p><p class="headingAnchor" id="H863188479"><span class="h1">ADJUNCTIVE THERAPIES</span><span class="headingEndMark"> — </span>Adjunctive therapies, including immunomodulatory therapies (eg, granulocyte-colony stimulating factor [G-CSF]), granulocyte-macrophage colony stimulating factor (GM-CSF), and hyperbaric oxygen therapy, require further study.</p><p class="headingAnchor" id="H863188602"><span class="h2">Immunomodulatory therapies</span><span class="headingEndMark"> — </span>As noted above, in patients receiving immunosuppressive therapy (eg, hematopoietic and solid organ transplant recipients), we reduce immunosuppression when feasible.</p><p>Several studies have examined the role of immune modulation in the treatment of fungal infections. These include cellular growth factors (eg, granulocyte-colony stimulating factor), cytokines such as the proinflammatory cytokines interferon (IFN)-gamma or interleukin-12, monoclonal antibodies, granulocyte infusions, immunoglobulin infusions, and active immunization [<a href="#rid112">112,113</a>].</p><p>The use of adjunctive G-CSF or GM-CSF for recovery of neutropenia [<a href="#rid51">51,79,114</a>] or the use of IFN-gamma [<a href="#rid59">59</a>] have been reported in isolated cases, but no firm conclusions can be drawn about their efficacy. In a case series of patients with <em>L. prolificans</em> infections, survival was independently associated with recovery from neutropenia [<a href="#rid107">107</a>]. However, studies in animal models have not demonstrated improved survival or differences in fungal burden with the addition of G-CSF to either amphotericin B formulations or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> [<a href="#rid115">115,116</a>]. Nevertheless, in neutropenic patients with scedosporiosis, adjunctive G-CSF or GM-CSF can be considered.</p><p>In in vitro studies, <em>Scedosporium</em> and <em>Lomentospora</em> species were vulnerable to polymorphonuclear leukocytes (PMNs) and macrophages, especially when opsonization of hyphae occurred [<a href="#rid117">117,118</a>]. In vitro studies of the combination of various antifungals (<a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, amphotericin) plus PMNs against <em>S. apiospermum</em> and <em>L. prolificans</em> suggest possible additive or synergistic effects [<a href="#rid119">119,120</a>]. The combination of posaconazole plus PMNs appeared to have synergistic activity against <em>L. prolificans</em> isolates but additive effects against <em>S. apiospermum</em>.</p><p class="headingAnchor" id="H863184104"><span class="h2">Hyperbaric oxygen therapy</span><span class="headingEndMark"> — </span>Another approach that warrants further study is the use of a hyperbaric oxygen therapy. In vitro testing showed that all antifungal agents had low minimum inhibitory concentrations (MICs) when incubated with <em>S. apiospermum</em> and <em>L. prolificans</em> isolates in a hyperbaric atmosphere [<a href="#rid121">121</a>]. However, the MICs reverted to the expected high values when the incubation was performed in a normal atmosphere. It is unknown whether exposing patients with <em>Scedosporium</em> infections to a hyperbaric atmosphere would improve the efficacy of antifungal therapy.</p><p class="headingAnchor" id="H31"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>As noted above, <em>Scedosporium</em> and <em>Lomentospora</em> infections are associated with a high incidence of disseminated disease and high mortality rates in hematopoietic cell and solid organ transplant recipients; mortality rates have ranged from 40 to 100 percent [<a href="#rid44">44-47,49,51,107,122</a>]. Treatment failures are especially common in patients with <em>L. prolificans</em> infection. The majority of patients with respiratory, central nervous system, or disseminated <em>L. prolificans</em> infections have succumbed regardless of the antifungal regimen [<a href="#rid48">48,49,51,83,111,123-130</a>]. (See <a class="local">'Lomentospora prolificans'</a> above.)</p><p>The outcome of <em>Scedosporium</em> and <em>Lomentospora</em> infection depends upon the immune status of the host, the location and extent of the infection, and whether surgical debridement is possible.</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – <em>Scedosporium</em> and <em>Lomentospora</em> are filamentous fungi ubiquitous in the environment. The two major human pathogens within this genus are <em>Scedosporium apiospermum</em> and <em>Lomentospora prolificans</em>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Susceptibility testing</strong> – We send clinical isolates for susceptibility testing from all patients with <em>Scedosporium</em> or <em>Lomentospora</em> infection. (See <a class="local">'Susceptibility testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal selection</strong> – Antifungal therapy should be initiated as soon as possible for <em>Scedosporium</em> or <em>Lomentospora</em> infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the empiric treatment of <em>S. apiospermum</em> infections, we suggest <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> monotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Scedosporium apiospermum'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>L. prolificans</em> is resistant to most of the antifungal agents available. For empiric therapy of <em>L. prolificans</em> infection, we suggest <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> plus <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> with or without an echinocandin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Lomentospora (formerly Scedosporium) prolificans'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The antifungal regimen should be tailored according to in vitro susceptibility results. (See <a class="local">'Choice of regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing immunosuppression</strong> – In patients receiving immunosuppressive therapy (eg, hematopoietic cell and solid organ transplant recipients), we reduce immunosuppression when feasible. (See <a class="local">'Antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of debridement</strong> – Surgical debridement should be performed when feasible (ie, when infection is localized) as it has been associated with improved outcomes. (See <a class="local">'Surgical debridement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of G-CSF</strong> – In neutropenic patients, granulocyte-colony stimulating factor to hasten recovery from neutropenia can be considered, although further study is needed to establish its efficacy. (See <a class="local">'Immunomodulatory therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – <em>Scedosporium</em> and <em>Lomentospora</em> infections are associated with a high incidence of disseminated disease and high mortality rates in hematopoietic cell and solid organ transplant recipients; mortality rates have ranged from 40 to 100 percent. The site of infection and underlying immune status of the host play an important role in the response to therapy and survival. Treatment failures are especially common in patients with <em>L. prolificans</em> infection. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.</a></li><li><a class="nounderline abstract_t">Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 2003; 119:854.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl 1:48.</a></li><li><a class="nounderline abstract_t">Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 Suppl 2:S112.</a></li><li><a class="nounderline abstract_t">Lamoth F, Kontoyiannis DP. Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients. Antimicrob Agents Chemother 2019; 63.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. M 38: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA. 2018.</li><li><a class="nounderline abstract_t">Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43:5243.</a></li><li><a class="nounderline abstract_t">Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917.</a></li><li><a class="nounderline abstract_t">Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43:149.</a></li><li><a class="nounderline abstract_t">Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741.</a></li><li><a class="nounderline abstract_t">Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62.</a></li><li><a class="nounderline abstract_t">Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Carvalhaes CG, Messer SA, et al. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. Diagn Microbiol Infect Dis 2021; 101:115473.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Carvalhaes CG, Rhomberg P, et al. Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019). J Antibiot (Tokyo) 2021; 74:519.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291.</a></li><li><a class="nounderline abstract_t">Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396.</a></li><li><a class="nounderline abstract_t">Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012; 56:2635.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Rhomberg PR, Wiederhold NP, et al. In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Messer SA, Carvalhaes CG, Castanheira M, Pfaller MA. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. Diagn Microbiol Infect Dis 2020; 97:115007.</a></li><li><a class="nounderline abstract_t">Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med Mycol 2018; 56:1050.</a></li><li><a class="nounderline abstract_t">Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother 2020; 75:3582.</a></li><li><a class="nounderline abstract_t">Garcia-Effron G, Gomez-Lopez A, Mellado E, et al. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004; 53:1086.</a></li><li><a class="nounderline abstract_t">Wiederhold NP. Review of the Novel Investigational Antifungal Olorofim. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Wiederhold NP, Law D, Birch M. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. J Antimicrob Chemother 2017; 72:1977.</a></li><li><a class="nounderline abstract_t">Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents 2020; 56:106105.</a></li><li><a class="nounderline abstract_t">Singh A, Singh P, Meis JF, Chowdhary A. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother 2021; 76:1229.</a></li><li><a class="nounderline abstract_t">Georgacopoulos O, Nunnally N, Law D, et al. In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans. Microbiol Spectr 2023; 11:e0278922.</a></li><li><a class="nounderline abstract_t">Escribano P, Gómez A, Reigadas E, et al. EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings. Antimicrob Agents Chemother 2022; 66:e0084922.</a></li><li><a class="nounderline abstract_t">Seyedmousavi S, Chang YC, Youn JH, et al. In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis. Antimicrob Agents Chemother 2021; 65:e0043421.</a></li><li class="breakAll">Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT03583164?term=NCT03583164&amp;draw=2&amp;rank=1 (Accessed on March 21, 2023).</li><li><a class="nounderline abstract_t">Pfaller MA, Huband MD, Flamm RK, et al. In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother 2019; 74:1295.</a></li><li><a class="nounderline abstract_t">Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Huband MD, Rhomberg PR, et al. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020). Antimicrob Agents Chemother 2022; 66:e0102822.</a></li><li class="breakAll">Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04240886 (Accessed on March 21, 2023).</li><li><a class="nounderline abstract_t">Wu Y, Grossman N, Totten M, et al. Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates. Antimicrob Agents Chemother 2020; 64.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. M 38M51S: Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi, 3rd Edition. Clinical and Laboratory Standards Institute, Wayne, PA. 2022.</li><li><a class="nounderline abstract_t">Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 2015; 59:4308.</a></li><li><a class="nounderline abstract_t">Chu S, Long L, Sherif R, et al. A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates. Antimicrob Agents Chemother 2021; 65.</a></li><li><a class="nounderline abstract_t">Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44:470.</a></li><li><a class="nounderline abstract_t">Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47:106.</a></li><li><a class="nounderline abstract_t">Biswas C, Sorrell TC, Djordjevic JT, et al. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother 2013; 68:2842.</a></li><li><a class="nounderline abstract_t">Heyn K, Tredup A, Salvenmoser S, Müller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49:5157.</a></li><li><a class="nounderline abstract_t">Husain S, Muñoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89.</a></li><li><a class="nounderline abstract_t">Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37:221.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.</a></li><li><a class="nounderline abstract_t">Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743.</a></li><li><a class="nounderline abstract_t">Seidel D, Meißner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol 2019; 45:1.</a></li><li><a class="nounderline abstract_t">Bronnimann D, Garcia-Hermoso D, Dromer F, et al. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification. Med Mycol 2021; 59:486.</a></li><li><a class="nounderline abstract_t">Blez D, Bronnimann D, Rammaert B, et al. Invasive bone and joint infections from the French Scedosporiosis/lomentosporiosis Observational Study (SOS) cohort: no mortality with long-term antifungal treatment and surgery. Med Mycol 2023; 61.</a></li><li><a class="nounderline abstract_t">Neoh CF, Chen SCA, Crowe A, et al. Invasive Scedosporium and Lomentospora prolificans Infections in Australia: A Multicenter Retrospective Cohort Study. Open Forum Infect Dis 2023; 10:ofad059.</a></li><li class="breakAll">Vfend (voriconazole) for oral use, for oral suspension, for injection, for intravenous use, prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=618 (Accessed on November 12, 2008).</li><li><a class="nounderline abstract_t">Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis 2021; 21:e246.</a></li><li><a class="nounderline abstract_t">Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6:S401.</a></li><li><a class="nounderline abstract_t">Capilla J, Mayayo E, Serena C, et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother 2004; 54:1092.</a></li><li><a class="nounderline abstract_t">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a class="nounderline abstract_t">Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36:1436.</a></li><li><a class="nounderline abstract_t">Muñoz P, Marín M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499.</a></li><li><a class="nounderline abstract_t">Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998; 27:1437.</a></li><li><a class="nounderline abstract_t">Klopfenstein KJ, Rosselet R, Termuhlen A, Powell D. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol 2003; 41:494.</a></li><li><a class="nounderline abstract_t">Perlroth MG, Miller J. Pseudoallescheria boydii pneumonia and empyema: a rare complication of heart transplantation cured with voriconazole. J Heart Lung Transplant 2004; 23:647.</a></li><li><a class="nounderline abstract_t">García-Arata MI, Otero MJ, Zomeño M, et al. Scedosporium apiospermum pneumonia after autologous bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1996; 15:600.</a></li><li><a class="nounderline abstract_t">Nomdedéu J, Brunet S, Martino R, et al. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis 1993; 16:731.</a></li><li><a class="nounderline abstract_t">Goldberg SL, Geha DJ, Marshall WF, et al. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993; 16:803.</a></li><li><a class="nounderline abstract_t">Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43:973.</a></li><li><a class="nounderline abstract_t">Talbot TR, Hatcher J, Davis SF, et al. Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Transplantation 2002; 74:1645.</a></li><li><a class="nounderline abstract_t">German JW, Kellie SM, Pai MP, Turner PT. Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis. Case report. Neurosurg Focus 2004; 17:E9.</a></li><li><a class="nounderline abstract_t">O'Doherty M, Hannan M, Fulcher T. Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host. Orbit 2005; 24:285.</a></li><li><a class="nounderline abstract_t">Karaarslan A, Arikan S, Karaarslan F, Cetin ES. Skin infection caused by Scedosporium apiospermum. Mycoses 2003; 46:524.</a></li><li><a class="nounderline abstract_t">Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648.</a></li><li><a class="nounderline abstract_t">Capilla J, Serena C, Pastor FJ, et al. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother 2003; 47:3976.</a></li><li><a class="nounderline abstract_t">Capilla J, Guarro J. Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother 2004; 48:4009.</a></li><li><a class="nounderline abstract_t">González GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003; 47:1436.</a></li><li><a class="nounderline abstract_t">Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387:760.</a></li><li class="breakAll">Cornely OA. Outcomes in patients with invasive mould disease caused by Fusarium or Scedosporium spp treated with isavuconazole: Experience from the VITAL and SECURE trials. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy [ICAAC]; Washington, DC September 5–9, 2014; M-1760.</li><li><a class="nounderline abstract_t">Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41:3981.</a></li><li><a class="nounderline abstract_t">Martin-Vicente A, Guarro J, Capilla J. Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation. Int J Antimicrob Agents 2017; 49:422.</a></li><li><a class="nounderline abstract_t">Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46:233.</a></li><li><a class="nounderline abstract_t">Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111.</a></li><li><a class="nounderline abstract_t">Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008; 10:63.</a></li><li><a class="nounderline abstract_t">Ochi Y, Hiramoto N, Takegawa H, et al. Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy. Int J Hematol 2015; 101:620.</a></li><li><a class="nounderline abstract_t">Wangchinda W, Chongtrakool P, Tanboon J, Jitmuang A. Lomentospora prolificans vertebral osteomyelitis with spinal epidural abscess in an immunocompetent woman: Case report and literature review. Med Mycol Case Rep 2018; 21:26.</a></li><li><a class="nounderline abstract_t">Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry. Mycoses 2020; 63:437.</a></li><li><a class="nounderline abstract_t">Dolton MJ, Perera V, Pont LG, McLachlan AJ. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother 2014; 58:48.</a></li><li><a class="nounderline abstract_t">Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47:62.</a></li><li><a class="nounderline abstract_t">Sullivan LJ, Snibson G, Joseph C, Taylor HR. Scedosporium prolificans sclerokeratitis. Aust N Z J Ophthalmol 1994; 22:207.</a></li><li><a class="nounderline abstract_t">Taylor A, Wiffen SJ, Kennedy CJ. Post-traumatic Scedosporium inflatum endophthalmitis. Clin Exp Ophthalmol 2002; 30:47.</a></li><li><a class="nounderline abstract_t">Vagefi MR, Kim ET, Alvarado RG, et al. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J Ophthalmol 2005; 139:370.</a></li><li><a class="nounderline abstract_t">Wilson CM, O'Rourke EJ, McGinnis MR, Salkin IF. Scedosporium inflatum: clinical spectrum of a newly recognized pathogen. J Infect Dis 1990; 161:102.</a></li><li><a class="nounderline abstract_t">Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14:1027.</a></li><li><a class="nounderline abstract_t">Pickles RW, Pacey DE, Muir DB, Merrell WH. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. J Infect 1996; 33:193.</a></li><li><a class="nounderline abstract_t">Rodríguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother 2009; 53:2153.</a></li><li><a class="nounderline abstract_t">Bocanegra R, Najvar LK, Hernandez S, et al. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis. Antimicrob Agents Chemother 2005; 49:5139.</a></li><li><a class="nounderline abstract_t">Heath CH, Slavin MA, Sorrell TC, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009; 15:689.</a></li><li><a class="nounderline abstract_t">Lackner M, Hagen F, Meis JF, et al. Susceptibility and diversity in the therapy-refractory genus scedosporium. Antimicrob Agents Chemother 2014; 58:5877.</a></li><li><a class="nounderline abstract_t">Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis 2015; 34:1289.</a></li><li><a class="nounderline abstract_t">Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros 2015; 14:237.</a></li><li><a class="nounderline abstract_t">Gilgado F, Serena C, Cano J, et al. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006; 50:4211.</a></li><li><a class="nounderline abstract_t">Castanheira M, Duncanson FP, Diekema DJ, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother 2012; 56:352.</a></li><li><a class="nounderline abstract_t">Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.</a></li><li><a class="nounderline abstract_t">Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106:2641.</a></li><li><a class="nounderline abstract_t">Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743.</a></li><li><a class="nounderline abstract_t">Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.</a></li><li><a class="nounderline abstract_t">Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.</a></li><li><a class="nounderline abstract_t">Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630.</a></li><li><a class="nounderline abstract_t">Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl 1:S28.</a></li><li><a class="nounderline abstract_t">Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47:359.</a></li><li><a class="nounderline abstract_t">Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole. Case report. J Neurosurg 2005; 103:83.</a></li><li><a class="nounderline abstract_t">Mursch K, Trnovec S, Ratz H, et al. Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode. Childs Nerv Syst 2006; 22:189.</a></li><li><a class="nounderline abstract_t">Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31:673.</a></li><li><a class="nounderline abstract_t">Seidel D, Hassler A, Salmanton-García J, et al. Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope® and the literature. Int J Infect Dis 2020; 92:114.</a></li><li><a class="nounderline abstract_t">Casadevall A, Pirofski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis 2001; 33:1048.</a></li><li><a class="nounderline abstract_t">Pappas PG. Immunotherapy for invasive fungal infections: from bench to bedside. Drug Resist Updat 2004; 7:3.</a></li><li><a class="nounderline abstract_t">Bouza E, Muñoz P, Vega L, et al. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23:192.</a></li><li><a class="nounderline abstract_t">Ortoneda M, Capilla J, Pastor FJ, et al. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50:247.</a></li><li><a class="nounderline abstract_t">Simitsopoulou M, Gil-Lamaignere C, Avramidis N, et al. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother 2004; 48:3801.</a></li><li><a class="nounderline abstract_t">Gil-Lamaignere C, Roilides E, Lyman CA, et al. Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury. Infect Immun 2003; 71:6472.</a></li><li><a class="nounderline abstract_t">Gil-Lamaignere C, Winn RM, Simitsopoulou M, et al. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol 2005; 43:253.</a></li><li><a class="nounderline abstract_t">Gil-Lamaignere C, Roilides E, Mosquera J, et al. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46:2234.</a></li><li><a class="nounderline abstract_t">Vikelouda K, Simitsopoulou M, Antachopoulos C, et al. Pharmacodynamic and immunological interactions of amphotericin B formulations and voriconazole with human neutrophils against mature Scedosporium apiospermum and Fusarium spp. biofilms. J Antimicrob Chemother 2023; 78:1076.</a></li><li><a class="nounderline abstract_t">Farina C, Marchesi G, Passera M, et al. Comparative study of the in vitro activity of various antifungal drugs against Scedosporium spp. in aerobic and hyperbaric atmosphere versus normal atmosphere. J Mycol Med 2012; 22:142.</a></li><li><a class="nounderline abstract_t">Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis 2014; 16:578.</a></li><li><a class="nounderline abstract_t">Idigoras P, Pérez-Trallero E, Piñeiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32:E158.</a></li><li><a class="nounderline abstract_t">Berenguer J, Rodríguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76:256.</a></li><li><a class="nounderline abstract_t">Madrigal V, Alonso J, Bureo E, et al. Fatal meningoencephalitis caused by Scedosporium inflatum (Scedosporium prolificans) in a child with lymphoblastic leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:601.</a></li><li><a class="nounderline abstract_t">Salesa R, Burgos A, Ondiviela R, et al. Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation. Scand J Infect Dis 1993; 25:389.</a></li><li><a class="nounderline abstract_t">de Batlle J, Motjé M, Balanzà R, et al. Disseminated infection caused by Scedosporium prolificans in a patient with acute multilineal leukemia. J Clin Microbiol 2000; 38:1694.</a></li><li><a class="nounderline abstract_t">Rabodonirina M, Paulus S, Thevenet F, et al. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis 1994; 19:138.</a></li><li><a class="nounderline abstract_t">Spielberger RT, Tegtmeier BR, O'Donnell MR, Ito JI. Fatal Scedosporium prolificans (S. inflatum) fungemia following allogeneic bone marrow transplantation: report of a case in the United States. Clin Infect Dis 1995; 21:1067.</a></li><li><a class="nounderline abstract_t">Jenks JD, Seidel D, Cornely OA, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. Clin Microbiol Infect 2020; 26:784.e1.</a></li></ol></div><div id="topicVersionRevision">Topic 2429 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731939" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817433" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14748802" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections due to emerging and uncommon medically important fungal pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722837" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The new fungal opportunists are coming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31481441" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31481441" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16207990" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495251" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381115" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052897" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751112" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202441" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Infections caused by Scedosporium spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352433" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34188199" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20524153" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18212101" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30061288" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32081523" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370408" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32856079" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15102749" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32751765" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Review of the Novel Investigational Antifungal Olorofim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333310" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32721601" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33421073" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36629417" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35924916" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34252298" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34252298" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182527" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753499" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31818813" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36286491" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36286491" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32816726" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32816726" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25896696" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33317999" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10639389" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12499177" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861311" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304192" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15614697" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12856215" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880955" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18212110" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30628529" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33037432" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36813259" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Invasive bone and joint infections from the French Scedosporiosis/lomentosporiosis Observational Study (SOS) cohort: no mortality with long-term antifungal treatment and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36861090" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Invasive Scedosporium and Lomentospora prolificans Infections in Australia: A Multicenter Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36861090" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Invasive Scedosporium and Lomentospora prolificans Infections in Australia: A Multicenter Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33606997" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809926" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509616" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715306" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Voriconazole treatment for less-common, emerging, or refractory fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9574724" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096022" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9868657" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14515403" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135387" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pseudoallescheria boydii pneumonia and empyema: a rare complication of heart transplantation cured with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874080" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Scedosporium apiospermum pneumonia after autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8389611" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8392389" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695722" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490804" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636579" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354641" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14641629" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Skin infection caused by Scedosporium apiospermum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032903" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of Scedosporium apiospermum brain abscesses with posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638514" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388467" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654687" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684607" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684607" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904435" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257903" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801370" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627286" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428274" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25630434" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073138" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lomentospora prolificans vertebral osteomyelitis with spinal epidural abscess in an immunocompetent woman: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080902" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope®registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126579" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998402" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818880" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Scedosporium prolificans sclerokeratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11885796" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Post-traumatic Scedosporium inflatum endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734012" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2295842" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Scedosporium inflatum: clinical spectrum of a newly recognized pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534693" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical features of human infection with Scedosporium inflatum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8945709" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223617" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304187" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549223" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070092" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Susceptibility and diversity in the therapy-refractory genus scedosporium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894985" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595044" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015631" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083469" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167683" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998833" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Improved outcome in central nervous system aspergillosis, using voriconazole treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356792" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171251" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017830" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594645" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Voriconazole: a new triazole antifungal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Pharmacology of systemic antifungal agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19031336" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16122011" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Scedosporium apiospermum brain abscess treated with surgery and voriconazole. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15864705" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017814" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863876" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope®and the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528579" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Adjunctive immune therapy for fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15072766" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Immunotherapy for invasive fungal infections: from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816160" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582297" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388437" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573669" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010852" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069979" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36848199" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pharmacodynamic and immunological interactions of amphotericin B formulations and voriconazole with human neutrophils against mature Scedosporium apiospermum and Fusarium spp. biofilms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518016" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Comparative study of the in vitro activity of various antifungal drugs against Scedosporium spp. in aerobic and hyperbaric atmosphere versus normal atmosphere.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24962102" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11340550" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279332" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7588846" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Fatal meningoencephalitis caused by Scedosporium inflatum (Scedosporium prolificans) in a child with lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8362236" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10747173" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Disseminated infection caused by Scedosporium prolificans in a patient with acute multilineal leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948515" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645825" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Fatal Scedosporium prolificans (S. inflatum) fungemia following allogeneic bone marrow transplantation: report of a case in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31972317" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope®registry 2008-2019.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
